38239-46-2

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-3-METHYLTHIOPHENE-2-CARBALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and functional groups contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 5-BROMO-3-METHYLTHIOPHENE-2-CARBALDEHYDE serves as an intermediate for the production of agrochemicals. Its role in creating effective compounds for pest control and crop protection is significant.
Used in Organic Synthesis:
5-BROMO-3-METHYLTHIOPHENE-2-CARBALDEHYDE is utilized as a versatile building block in organic synthesis. Its ability to form diverse molecular architectures is essential for creating a wide range of organic compounds with different applications.
Used in Medicinal Chemistry Research:
5-BROMO-3-METHYLTHIOPHENE-2-CARBALDEHYDE is also used as a target in medicinal chemistry research due to its various biological activities. Its potential in developing new therapeutic agents is under investigation, making it a valuable asset in the field of drug discovery.

Upstream product

• 5834-16-2 3-methyl-2-thiophenecarboxaldehdye 

Relevant academic research and scientific papers

Novel dye sensitizers of main chain polymeric metal complexes based on complexes of diaminomaleonitrile with Cd(II), Ni(II): Synthesis, characterization, and photovoltaic performance for dye-sensitized solar cells

Four new donor-π-acceptor (D-π-A) dyes (P1, P2, P3, P4) were synthesized, characterized and applied in dye-sensitized solar cells (DSSCs). Poly(p-phenylenevinylene) (PPV) or Bisthien PPV was used as donor, ethilenic link or thiophene as π-bridge, and Cadmium complexes or Nickel complexes as acceptor in these D-π-A type sensitizers. The introduction of the polymerization of π system and the metal complexes has greatly increased the light absorption. Increasing the number of thienyl group in the molecule to a certain extent was effective in further lowering both the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) energy levels to attain higher open-circuit voltage (Voc). Among them, P3-based cell shows excellent photovoltaic performance and power conversion efficiency up to 2.25% under AM 1.5G irradiation (100 mW cm -2).

Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates

In order to further enhance the anti-Aspergillus efficacy of our previously discovered antifungal lead compounds (I), two series of novel azoles featuring thieno[2,3-c]pyrrolidone and thieno[3,2-c]pyrrolidone nuclei were designed and evaluated for their in vitro activity on the basis of the binding mode of albaconazole using molecular docking, along with SARs of antifungal triazoles. Most of target compounds exhibited excellent activity against Candida and Cryptococcus spp., with MIC values in the range of 0.0625 μg/ml to 0.0156 μg/ml. The thieno[3,2-c]pyrrolidone unit was more suited for improving activity against Aspergillus spp. The most potent compound, 18a, was selected for further development due to its significant in vitro activity against Aspergillus spp. (MIC Combining double low line 0.25 μg/ml), as well as its high metabolic stability in human liver microsomes.

OXAZOLE AND ISOXAZOLE CRAC MODULATORS

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, Formula Ia, R4, R5, Formula Ib, R3, R3a, W, D, R2a, R2b and R2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.

BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL

The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndr

Novel thienopyridine compounds, and methods of use thereof

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).

Caspase inhibitors and uses thereof

The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of th

Butenoic acid derivatives

A butenoic acid compound is defined by the following formula: STR1 in which Z is O,S, vinylene or azomethyne, A is an alkylene and J is phenyl or etc. It is useful to treat the heart disease.